{"id":63920,"date":"2026-04-24T21:15:14","date_gmt":"2026-04-24T13:15:14","guid":{"rendered":"https:\/\/flcube.com\/?p=63920"},"modified":"2026-04-24T21:15:15","modified_gmt":"2026-04-24T13:15:15","slug":"sisram-medical-forges-strategic-alliance-for-daxxify-commercialization-in-chinas-long-acting-botulinum-toxin-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63920","title":{"rendered":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#8217;s Long-Acting Botulinum Toxin Market"},"content":{"rendered":"\n<p><strong>Sisram Medical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1696:HKG\">HKG: 1696<\/a>), an Israel-based aesthetic medical technology company and subsidiary of <strong>Fosun Pharmaceutical Group<\/strong>, announced a strategic partnership with <strong>U.S.-based Revance Therapeutics, Inc.<\/strong> and <strong>Shanghai Fosun Pharmaceutical Development Co., Ltd.<\/strong> The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for <strong>Daxxify<\/strong>, the world&#8217;s first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Lead Company<\/strong><\/td><td>Sisram Medical Ltd (HKG: 1696)<\/td><\/tr><tr><td><strong>Partners<\/strong><\/td><td>Revance Therapeutics, Inc. &amp; Shanghai Fosun Pharmaceutical Development Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Daxxify (long-acting botulinum toxin type A)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Proprietary peptide exchange technology<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>January 2026 in China<\/td><\/tr><tr><td><strong>Partnership Focus<\/strong><\/td><td>Long-term strategic framework and key commercial terms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-innovation-amp-market-positioning\">Product Innovation &amp; Market Positioning<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-technological-differentiation\">Technological Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class<\/strong>: World&#8217;s first long-acting botulinum toxin type A<\/li>\n\n\n\n<li><strong>Proprietary Platform<\/strong>: Peptide exchange technology enabling extended duration<\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: Addresses demand for longer-lasting aesthetic treatments with reduced retreatment frequency<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-advantages\">Commercial Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Duration Profile<\/strong>: Significantly extended effect duration compared to conventional botulinum toxins<\/li>\n\n\n\n<li><strong>Patient Appeal<\/strong>: Reduced treatment frequency enhances convenience and compliance<\/li>\n\n\n\n<li><strong>Provider Benefits<\/strong>: Streamlined scheduling and improved patient retention<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-resource-integration\">Strategic Resource Integration<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fosun-pharmaceutical-development-strengths\">Fosun Pharmaceutical Development Strengths<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Industry Chain Integration<\/strong>: Deep resource accumulation across entire pharmaceutical value chain<\/li>\n\n\n\n<li><strong>Industrial Influence<\/strong>: Established market presence and regulatory expertise in China<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Comprehensive distribution and marketing capabilities<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revance-therapeutics-expertise\">Revance Therapeutics Expertise<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technological Leadership<\/strong>: Cutting-edge expertise in injectable filler technologies<\/li>\n\n\n\n<li><strong>R&amp;D Capabilities<\/strong>: Core product development advantages in aesthetic therapeutics<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Proprietary platform technologies beyond Daxxify<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sisram-medical-contribution\">Sisram Medical Contribution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Channel Deployment<\/strong>: International distribution network and market access<\/li>\n\n\n\n<li><strong>Operational Excellence<\/strong>: Refined operational strengths in aesthetic medical device commercialization<\/li>\n\n\n\n<li><strong>Cross-Border Coordination<\/strong>: Bridge between Western innovation and Chinese market execution<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-acceleration-strategy\">Market Acceleration Strategy<\/h2>\n\n\n\n<p>The tripartite alliance aims to comprehensively accelerate Daxxify&#8217;s commercialization in China through:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Leveraging Fosun&#8217;s established healthcare ecosystem<\/li>\n\n\n\n<li>Utilizing Revance&#8217;s technological and regulatory expertise<\/li>\n\n\n\n<li>Deploying Sisram&#8217;s global channel optimization capabilities<\/li>\n\n\n\n<li>Implementing refined operational strategies for rapid market penetration<\/li>\n<\/ul>\n\n\n\n<p>China represents one of the world&#8217;s fastest-growing aesthetic markets, with botulinum toxin treatments experiencing double-digit annual growth. Daxxify&#8217;s unique long-acting profile positions it to capture premium market segments seeking enhanced convenience and efficacy.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding strategic partnerships, commercial timelines, and market positioning. Actual commercial outcomes, market share capture, and revenue generation may differ based on competitive dynamics, regulatory considerations, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1180,100,357],"class_list":["post-63920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-1696","tag-medical-aesthetics","tag-sisram-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#039;s Long-Acting Botulinum Toxin Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world&#039;s first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63920\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#039;s Long-Acting Botulinum Toxin Market\" \/>\n<meta property=\"og:description\" content=\"Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world&#039;s first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63920\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T13:15:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T13:15:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#8217;s Long-Acting Botulinum Toxin Market\",\"datePublished\":\"2026-04-24T13:15:14+00:00\",\"dateModified\":\"2026-04-24T13:15:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2403.webp\",\"keywords\":[\"HKG: 1696\",\"Medical aesthetics\",\"Sisram Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63920#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63920\",\"name\":\"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China's Long-Acting Botulinum Toxin Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2403.webp\",\"datePublished\":\"2026-04-24T13:15:14+00:00\",\"dateModified\":\"2026-04-24T13:15:15+00:00\",\"description\":\"Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world's first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63920\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2403.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China's Long-Acting Botulinum Toxin Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63920#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#8217;s Long-Acting Botulinum Toxin Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China's Long-Acting Botulinum Toxin Market - Insight, China&#039;s Pharmaceutical Industry","description":"Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world's first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63920","og_locale":"en_US","og_type":"article","og_title":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China's Long-Acting Botulinum Toxin Market","og_description":"Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world's first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.","og_url":"https:\/\/flcube.com\/?p=63920","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-24T13:15:14+00:00","article_modified_time":"2026-04-24T13:15:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63920#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63920"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#8217;s Long-Acting Botulinum Toxin Market","datePublished":"2026-04-24T13:15:14+00:00","dateModified":"2026-04-24T13:15:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63920"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp","keywords":["HKG: 1696","Medical aesthetics","Sisram Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63920#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63920","url":"https:\/\/flcube.com\/?p=63920","name":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China's Long-Acting Botulinum Toxin Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63920#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp","datePublished":"2026-04-24T13:15:14+00:00","dateModified":"2026-04-24T13:15:15+00:00","description":"Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world's first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63920#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63920"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63920#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp","width":1080,"height":608,"caption":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China's Long-Acting Botulinum Toxin Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63920#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China&#8217;s Long-Acting Botulinum Toxin Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63920"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63920\/revisions"}],"predecessor-version":[{"id":63923,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63920\/revisions\/63923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63922"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}